Ibogaine for Stroke Recovery: Evidence and Safety

A stroke occurs when blood flow to part of the brain is interrupted — by a clot or narrowed artery (ischaemic stroke) or by bleeding into brain tissue (haemorrhagic stroke). Deprived of oxygen, neurons in the affected territory die within minutes, and the functions that tissue supported are lost.

The American Heart Association's 2026 statistical update reports roughly 7.8 million US adults living with stroke, about 795,000 new or recurrent strokes each year, and a stroke death roughly every three minutes. Ischaemic strokes account for about 87% of cases. Stroke is the fifth leading cause of death in the US and a leading cause of long-term disability.

Survivors are left with combinations of hemiparesis (one-sided weakness), spasticity, impaired hand function, gait and balance problems, aphasia, visual field loss, swallowing difficulty, fatigue, cognitive change, and post-stroke depression.

The shape of recovery drives searches for experimental options. Improvement is fastest in the first weeks, most impairment-level recovery occurs within about three months, and measurable gains slow considerably after six months. Rehabilitation still produces benefit later, but the steep part of the curve is over.

That flattening is what families call the plateau, and it is from that position — not the acute hospital — that people begin asking whether something like ibogaine could restart the process.

Stroke care has two halves, and the evidence differs sharply between them.

The acute window is a genuine success story. Intravenous thrombolysis with alteplase or tenecteplase dissolves clots given within roughly 4.5 hours of onset. Mechanical thrombectomy removes large-vessel clots; in pooled analyses of the pivotal trials, the number needed to treat for one additional patient to reach functional independence at 90 days is roughly three to five — an unusually large effect in neurology. DAWN and DEFUSE-3 extended eligibility to 24 hours in carefully imaged patients. The limitation is reach, not efficacy: most people do not arrive in time.

Rehabilitation is the backbone of recovery. High-dose task-specific practice, constraint-induced movement therapy, physiotherapy, occupational and speech therapy all have supporting evidence. The CPASS trial (PNAS, 2021) found intensive motor training around 60 to 90 days post-stroke produced greater gains than the same training earlier or later — human evidence for a time-limited window of responsiveness.

One device therapy has randomised evidence in chronic stroke. In VNS-REHAB, 108 participants with chronic ischaemic stroke received intensive rehabilitation paired with active or sham vagus nerve stimulation. Fugl-Meyer Upper Extremity scores improved 5.0 points with active stimulation versus 2.4 with sham, response rates roughly doubled, and gains persisted at one year. The system is FDA-cleared.

Drug attempts to boost recovery have mostly failed. The small FLAME trial suggested fluoxetine improved motor scores; the far larger FOCUS, AFFINITY and EFFECTS trials — over 5,000 patients combined — found no improvement in functional outcome or motor recovery, while increasing fractures and seizures. That replication failure is the context for anything experimental.

Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga, studied mainly in substance use disorders. Interest in ibogaine for stroke recovery rests on mechanistic reasoning, not results. Three hypotheses are invoked.

1. Reopening a critical period. Nardou and colleagues reported in Nature (2023) that several psychedelics reopened the critical period for social reward learning in adult mice — a window normally closed after adolescence. Duration scaled with the drug, and ibogaine kept it open longest, about four weeks. If psychedelics restore juvenile-like malleability, pairing that state with intensive rehabilitation might let a chronically impaired brain relearn motor control. This is the rationale behind the psilocybin stroke trial now recruiting at Johns Hopkins.

2. Neurotrophic signalling. Ibogaine produces a sustained rise in glial cell line-derived neurotrophic factor (GDNF) via a self-reinforcing loop (He and colleagues, FASEB Journal, 2006). Marton and colleagues (Frontiers in Pharmacology, 2019) found GDNF mRNA rose roughly 12-fold in the rat ventral tegmental area, with BDNF changes in the nucleus accumbens — and BDNF is implicated in post-stroke plasticity.

3. Multi-receptor neurorestoration. Calvey and colleagues (Acta Neuropsychiatrica, 2026) argue ibogaine's affinities for NMDA, kappa-opioid and sigma receptors could combine to reduce excitotoxicity, regulate metabolism and support remyelination, explicitly linking white matter pathology to ischaemia and hypoxia.

The honest reading cuts against enthusiasm:

• The Nardou findings concern social behaviour in mice, not motor map reorganisation after a cortical infarct
• The GDNF and BDNF work was done in dopaminergic reward circuitry, to explain reduced drug intake; perilesional cortex was never examined
• The Acta Neuropsychiatrica paper is a narrative review, framed by its authors as a rationale for future investigation rather than evidence of effect
• NMDA antagonism cuts both ways. NMDA-blocking neuroprotectants repeatedly failed in human stroke trials, and NMDA signalling is required for the learning rehabilitation depends on

One point most pages about ibogaine for stroke recovery do not state plainly belongs first.

There is no published study of ibogaine in stroke. No randomised trial, no cohort study, no case series, and not one peer-reviewed case report of a stroke survivor treated with ibogaine, as of October 2026. There is also no animal study: a PubMed search combining ibogaine with stroke, cerebral ischaemia or middle cerebral artery occlusion returns seven records, none a study of ibogaine in a stroke model. Ibogaine has skipped the preclinical step stroke drug development normally requires.

The nearest human data concerns brain injury, not stroke. Tabaac, Carhart-Harris and Yung published a naturalistic case series in Frontiers in Pharmacology (2026) describing three patients with persistent symptoms after traumatic or hypoxic brain injury, treated with a six-week participant-directed iboga root bark microdosing protocol (0.1–1.0 g/day, assayed at 3.845% ibogaine, an estimated 3.8–38.5 mg/day ibogaine-equivalent) plus weekly psychotherapy. One participant — a 40-year-old woman with chronic hypoxic brain injury after an avalanche burial — is the closest published analogue to ischaemic injury. All three reported progressive improvement in headache, fatigue, brain fog, mood and sleep; two reported complete remission.

The authors' own conclusion is the appropriate one: the findings "do not establish causality or iboga-specific efficacy." Three patients, no controls, no blinding, no objective motor endpoints, psychotherapy throughout — and microdosing of root bark, not the high "flood" dose clinics use.

Two further studies are cited as if they were stroke evidence: a 2025 Frontiers in Immunology case report in two MS patients, and the 2024 Nature Medicine magnesium–ibogaine study, open-label in 30 veterans with TBI.

Ambio Life Sciences runs a Neuroregenerative Program accepting stroke alongside Parkinson's, MS, essential tremor, TBI and ALS, reporting roughly 30 patients supported since February 2025 and a Dalhousie University collaboration on neuroinflammatory biomarkers and stroke disease models. No outcome data from that cohort has been published; an enrolment figure is not a result.

Stroke has not been ignored by psychedelic researchers; the active work simply does not involve ibogaine.

Johns Hopkins PHATHOM (NCT07053917) is the first trial of a psychedelic for stroke recovery. Led by Gül Dölen, Steven Zeiler and John Krakauer, it began recruiting on 9 February 2026 and plans to enrol 20 adults whose ischaemic or haemorrhagic stroke occurred at least 12 months earlier, giving 25 mg of psilocybin (or two 12.5 mg doses) paired with enhanced motor training.

One detail is routinely misreported: PHATHOM's primary outcome is blood-pressure stability over 24 hours, a safety endpoint. Recovery from post-stroke deficits is secondary — even the flagship trial here is not yet testing whether the approach works.

The published case for the idea is a perspective piece, not data. Yang, Wang and Wang's "Harnessing psychedelics for stroke recovery" appeared in Brain (2025) as a four-page article arguing psychedelics hold untapped potential through neuroplasticity, reduced neuroinflammation, glutamate and mTOR signalling, and reactivation of perilesional and contralesional circuits. It is a hypothesis paper calling for trials.

Algernon NeuroScience took a different route with AP-188, intravenous DMT, completing a Phase 1 study in Leiden: a six-hour sub-psychedelic infusion reportedly reached plasma concentrations linked to neuroplasticity without a psychedelic experience. That is company-reported safety and pharmacokinetic data, with no efficacy outcome in stroke patients.

For ibogaine specifically, no stroke trial exists anywhere. The two state-funded US ibogaine programmes now getting underway target traumatic brain injury, PTSD and addiction, as described below.

Because ibogaine is Schedule I in the US, people seeking it travel to clinics where it is unscheduled or tolerated — most often Mexico, also Costa Rica and Portugal. Oversight varies widely, none of these programmes are approved stroke treatments anywhere, and treatment is self-funded.

A responsibly run programme should include, at minimum:

• 12-lead ECG with QTc measurement, plus cardiology clearance for any abnormality, and echocardiogram in anyone with vascular disease
• Metabolic panel with serum potassium and magnesium, corrected before dosing; liver and renal function; full blood count
• Complete medication reconciliation for QT-prolonging and serotonergic drugs
• CYP2D6 genotyping where available, since ibogaine is metabolised largely by CYP2D6 to noribogaine and poor metabolisers accumulate higher, longer exposure

For a stroke survivor, several additions are reasonable and absent from generic protocols: extended rhythm monitoring for occult atrial fibrillation, documented blood-pressure control, recent brain imaging, a swallowing assessment, and review by the stroke physician.

The acute flood dose involves hours of intense psychoactive effects then prolonged recovery, commonly with profound ataxia, nausea, vomiting, and inability to stand unassisted for many hours. Many clinics monitor cardiac rhythm for the first 12 hours — shorter than several cardiac safety reviews recommend, since noribogaine's half-life is roughly 28–49 hours, QT prolongation typically outlasts 24 hours, and documented adverse cardiac events have occurred 12 to 76 hours after dosing.

Low-dose protocols are a different exposure profile, and no published safety study has characterised chronic low-dose exposure to a hERG-blocking compound.

For stroke survivors the dominant question is not whether ibogaine works but whether it is survivable for them — and this is where condition and drug collide most directly.

The mechanism. Ibogaine and noribogaine block hERG potassium channels in cardiomyocytes, with IC50 values of approximately 4 µM and 3 µM respectively — concentrations reached at therapeutic doses (Koenig and Hilber, Molecules, 2015). The result is delayed repolarisation, a prolonged QT interval, and risk of torsades de pointes and cardiac arrest. QTc values of 480–700 ms have been documented, and between 1990 and 2008 19 deaths were temporally associated with ibogaine, six from acute cardiac causes. Hypokalaemia was present in every reviewed fatality, low magnesium in about half, and these events occurred at therapeutic doses in people with no known heart disease.

Why this matters more after a stroke. This population is unusually enriched for the exact factors that make hERG blockade dangerous:

• Atrial fibrillation is both a leading cause of ischaemic stroke and a frequent post-stroke finding — newly detected paroxysmal AF appears in roughly 9% of acute ischaemic stroke patients
• Stroke-heart syndrome means the baseline ECG may already be abnormal. QT prolongation is documented in 20–65% of acute stroke presentations, linked to insular damage and sympathetic overactivation, and prolonged QTc post-stroke predicts paroxysmal AF and ventricular arrhythmia
• The medication list is adversarial. Antiarrhythmics such as amiodarone and sotalol are themselves QT-prolonging, and SSRIs for post-stroke depression add serotonergic and QT concerns. No interaction data exist for ibogaine with direct oral anticoagulants
• Dysphagia and hemiparesis. Ibogaine reliably causes vomiting during hours of near-total immobility — a serious aspiration risk with impaired swallowing — and drug-induced ataxia compounds fall risk
• Haemorrhagic stroke and uncontrolled hypertension: psychoactive dosing produces blood-pressure swings, which is why PHATHOM made blood-pressure stability its primary endpoint. Post-stroke epilepsy adds a further unknown, since ibogaine's effect on seizure threshold is unstudied
• The cerebellum. Ibogaine's one well-characterised neurotoxicity is degeneration of cerebellar Purkinje cells via trans-synaptic excitotoxicity (O'Hearn and Molliver, 1997), in rats at 100 mg/kg — far above human therapeutic scaling. The cerebellum is also selectively vulnerable to ischaemia, and whether an already-injured brain is more susceptible is untested

Generally accepted absolute contraindications include long QT syndrome, structural heart disease, heart failure, recent myocardial infarction, uncorrected electrolytes, hepatic or renal impairment, pregnancy, and active psychosis. A large share of stroke survivors meet one.

One asymmetry deserves naming. In opioid use disorder, patients and clinicians sometimes accept ibogaine's arrhythmia risk because untreated addiction carries high near-term mortality. Stable chronic post-stroke disability does not — so that trade does not transfer here.

Legal status. Ibogaine is a Schedule I controlled substance under the US Controlled Substances Act — the most restrictive category, denoting high abuse potential and no currently accepted medical use. It is not approved for stroke recovery in any country.

The policy landscape is moving. Barrow Neurological Institute received $5 million from the Arizona Department of Health Services in 2026 for a double-blind, placebo-controlled Phase 1/2 trial in 40 participants with chronic traumatic brain injury, hoping to enrol its first participant in 2027 — the first ibogaine trial in the US. Texas has funded a statewide programme via UTHealth Houston and UTMB Galveston targeting addiction, TBI and behavioural health. Every funded ibogaine trial targets substance use disorder, PTSD or TBI; none includes stroke, and no ibogaine compound is on track for FDA approval before 2030.

What would advance the question:

• Any preclinical stroke study at all. MCAO or photothrombotic models are the standard screens for a candidate recovery agent; their absence is the single largest gap
• Motor outcomes that mean something — Fugl-Meyer or Action Research Arm Test scores with blinded raters, not the symptom self-report the existing case series relies on
• Pairing with training. If the mechanism is a reopened plasticity window, the drug alone should not be expected to reorganise motor maps — the psilocybin and DMT programmes pair drug with intensive rehabilitation deliberately
• Cardiac safety data in the excluded population — survivors on anticoagulants with abnormal baseline ECGs, exactly the people screened out of trials and accepted by clinics
• Evidence the critical-period window exists in humans, and a prospective registry, since people are already travelling

The honest bottom line. The evidence for ibogaine for stroke recovery is not thin — it is absent. No human stroke study, no animal stroke study, no case report. What exists is a mechanistic hypothesis assembled from mouse social behaviour, rodent reward circuitry, a narrative review, and a three-patient brain-injury case series whose authors decline to claim efficacy. Against that sits a documented, potentially fatal cardiac risk stroke survivors are more likely than most to carry.

The adjacent research is real and worth watching. The claim that ibogaine treats stroke is not.

---

This page is educational information, not medical advice. It does not recommend ibogaine or endorse any clinic. Decisions about stroke care belong with a treating neurologist. Do not stop anticoagulants, antiplatelets, antihypertensives or statins to pursue an experimental treatment — stopping secondary prevention substantially raises the risk of another stroke.